Literature DB >> 20594525

Catheter-Directed Intra-Arterial Abciximab Administration for Acute Thrombotic Occlusions during Neurointerventional Procedures.

I C Duncan1, P A Fourie.   

Abstract

SUMMARY: Abciximab is one of a new class of platelet aggregation inhibitors that has to date been used mainly in the management of acute coronary ischaemic syndromes or during cardiac intervention for the prevention and treatment of acute vessel occlusion during and after angioplasty or stent placement. More recently, it has begun to play a similar role in neurointerventional work. Its administration during acute stent or vessel occlusions has usually been via systemic intravenous infusion.We describe five cases of acute vessel occlusion during neurointerventional procedures where the abciximab bolus was administered intra-arterially at or close to the site of the occlusion, with rapid complete visual dissolution of the thrombus in four cases and partial dissolution in one, resulting in two patients with no neurological deficits, one with no further neurological deterioration, one with a mild residual thumb paresis and one with a severe neurological deficit.

Entities:  

Year:  2004        PMID: 20594525      PMCID: PMC3576593          DOI: 10.1177/159101990200800208

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  20 in total

1.  Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization.

Authors:  T E Lempert; A M Malek; V V Halbach; C C Phatouros; C F Dowd; R T Higashida
Journal:  Stroke       Date:  1999-03       Impact factor: 7.914

2.  Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.

Authors:  M A Memon; J C Blankenship; G C Wood; C M Frey; F J Menapace
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

3.  Transcatheter snare removal of acute middle cerebral artery thromboembolism: technical case report.

Authors:  B W Chopko; C Kerber; W Wong; B Georgy
Journal:  Neurosurgery       Date:  2000-06       Impact factor: 4.654

4.  Angioscopic evaluation of site-specific administration of ReoPro.

Authors:  S R Bailey; E O'Leary; R Chilton
Journal:  Cathet Cardiovasc Diagn       Date:  1997-10

5.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

Authors:  E M Antman; R P Giugliano; C M Gibson; C H McCabe; P Coussement; N S Kleiman; A Vahanian; A A Adgey; I Menown; H J Rupprecht; R Van der Wieken; J Ducas; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

Review 6.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.

Authors:  J Lefkovits; E F Plow; E J Topol
Journal:  N Engl J Med       Date:  1995-06-08       Impact factor: 91.245

7.  Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.

Authors:  S H Tam; P M Sassoli; R E Jordan; M T Nakada
Journal:  Circulation       Date:  1998-09-15       Impact factor: 29.690

8.  Use of anti-GP IIb-IIIa in acute thrombosis after intracoronary stent implantation.

Authors:  P Henry; K Boughalem; J P Rinaldi; S Makowski; K Khalife; J L Guermonprez; D Blanchard
Journal:  Cathet Cardiovasc Diagn       Date:  1998-01

9.  Efficacy of abciximab readministration in coronary intervention.

Authors:  M Madan; D J Kereiakes; J B Hermiller; M M Rund; G Tudor; L Anderson; M B McDonald; S D Berkowitz; M H Sketch; H R Phillips; J E Tcheng
Journal:  Am J Cardiol       Date:  2000-02-15       Impact factor: 2.778

10.  Abciximab rescue in acute carotid stent thrombosis.

Authors:  F C Tong; H J Cloft; G J Joseph; O B Samuels; J E Dion
Journal:  AJNR Am J Neuroradiol       Date:  2000-10       Impact factor: 3.825

View more
  7 in total

1.  Intra-Arterial Eptifibatide in the Management of Thromboembolism during Endovascular Treatment of Intracranial Aneurysms: Case Series and a Review of the Literature.

Authors:  Pankajavalli Ramakrishnan; Albert J Yoo; James D Rabinov; Christopher S Ogilvy; Joshua A Hirsch; Raul G Nogueira
Journal:  Interv Neurol       Date:  2013-10

2.  Periprocedural morbidity and mortality associated with endovascular treatment of intracranial aneurysms.

Authors:  Hae-Kwan Park; Michael Horowitz; Charles Jungreis; Julie Genevro; Christopher Koebbe; Elad Levy; Amin Kassam
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

3.  Safety of Abciximab injection during endovascular treatment of ruptured aneurysms.

Authors:  Jean-Christophe Gentric; Joelle Brisson; André Lima Batista; Jimmy Ghostine; Jean Raymond; Daniel Roy; Alain Weill
Journal:  Interv Neuroradiol       Date:  2015-05-11       Impact factor: 1.610

Review 4.  Is eptifibatide a safe and effective rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization? Single-center experience in 42 cases and review of the literature.

Authors:  Jacques Sedat; Yves Chau; Lydiane Mondot; Richard Chemla; Michel Lonjon; Bernard Padovani
Journal:  Neuroradiology       Date:  2013-11-27       Impact factor: 2.804

5.  Microsnare-assisted mechanical removal of intraprocedural distal middle cerebral arterial thromboembolism.

Authors:  Pieter Fourie; Ian C Duncan
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

6.  Local intra-arterial eptifibatide for intraoperative vessel thrombosis during aneurysm coiling.

Authors:  V Katsaridis; C Papagiannaki; N Skoulios; I Achoulias; D Peios
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 7.  Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist.

Authors:  Davide Simonato; Robin J Borchert; Marc-Antoine Labeyrie; Maurizio Fuschi; Lucie Thibault; Hans Henkes; David Fiorella; Benjamin Yq Tan; Leonard Ll Yeo; Hegoda Ld Makalanda; Ken Wong; Pervinder Bhogal
Journal:  Interv Neuroradiol       Date:  2021-05-04       Impact factor: 1.610

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.